Patients with refractory CMVemia after allogeneic hematopoietic stem cell transplantation
Conditions
Interventions
Experimental group: infusion the TCR-T cells
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients with acute leukemia (AL) or myelodysplastic syndrome (MDS) who receive haploid allogeneic hematopoietic stem cell transplantation, pre-transplantation assessment = 1000 copies/mL, and the CMV DNA copy number at the beginning of the treatment decreased by 3 weeks; 6. Patients who voluntarily sign informed consent and are willing to comply with treatment plans, visit arrangements, laboratory tests and other research procedures.
Exclusion criteria
Exclusion criteria: 1. Patients with active aGVHD III-IV and / or mild and severe cGVHD; 2. Have received cell therapy such as DLI, CTL, CAR-T, NK or participated in any other clinical research on drugs and medical devices; 3. Patients who have developed CMV disease; 4. Patients with organ failure: Heart: NYHA heart function grade IV; Liver: Grade C that achieves Child-Turcotte liver function grading; Kidney: kidney failure and uremia; Lung: symptoms of respiratory failure; Brain: a person with a disability; 5. Pregnant or lactating women; 6. The researchers found that it was unsuitable for the recipients to be enrolled.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| copy number of CMV DNA; | — |
Countries
China
Contacts
Public ContactLanping Xu
Peking University People's Hospital
Outcome results
None listed